Trial Profile
Retrospective Analysis of Genomic Landscape of ALK Positive NSCLC Prior to Ceritinib, and at Disease Progression Following Ceritinib
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ceritinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 01 Mar 2018 Status changed from recruiting to discontinued due to changes in treatment plans affecting drug therapy choices.
- 16 Feb 2017 Planned End Date changed from 1 Apr 2019 to 30 Apr 2019.
- 16 Feb 2017 Planned primary completion date changed from 1 Apr 2019 to 30 Apr 2019.